Mucosal, vulvovaginal, and urinary fungal infections are also well recognized. These are, generally, more frequent in patients treated with sodium-glucose cotransporter inhibitors. 4, 5 Systemic fungal infections are rare, even in those with DM, and often accompany prolonged hospitalization or a concurrent illness with associated added immunocompromise. 2, 3 Diabetic foot ulcerations (DFUs) are common in DM, reported to occur in 19% to 34% of patients during their lifetime. 6 More than half of these become infected at some point, negatively affecting clinical outcomes. 7 Thus far, we have virtually always focused on bacterial infections, and very little is known on fungal diabetic foot disease. Superficial fungi are known to be very frequent in the feet of those with long-standing DM: studies have reported an overall 52% to 86% prevalence. 3, 8 The main locations are the interdigital spaces and toenails, which consequently accompany an increased risk of classical diabetic foot disease. 8 Older age, male gender, and longer DM duration are also important risk factors. 3, 8 However, the prevalence rate and outcomes of true fungal infections in DFUs are elusive.
In one study from Zagreb, 9 22 out of 509 DFUs yielded Candida spp, suggesting a 4.3% total prevalence. Furthermore, in the study, mixed bacterial and fungal infections were twice as common as fungal-only infections. In another study from India, 10 48 out of 74 DFUs (65%) grew yeast or mold-like species. Candida spp, Trichosporon spp, Trichophyton spp, various Aspergillus spp, Fusarium spp, and Penicillium spp were the most common isolates. 10 Importantly, both these studies and other similar investigations into the presence of fungal organisms in DFUs 11 have selected patients with very long DFU duration and resistance to classical treatment strategies. Arguably, such selected patients represent a distinct subgroup of DFU. More recently, Kalan et al 12 investigated 100
nonhealing DFUs with high-throughput sequencing of the pan-fungal internal transcribed spacer 1 locus. They identified 17 phylotypes at a relative abundance of >1% and noted that the fungal mycobiome was heterogeneous with high interpersonal and -intrapersonal variance: 12 41% of samples demonstrated Cladosporium herbarum; 22% of samples had Candida albicans. Overall, as high as 80% of samples had evidence of fungal communities at some point during the longitudinal follow-up period. 12 Moreover, the presence of Ascomycota fungi at baseline was associated with slower healing, but the study was not designed to explicitly investigate this. 12 Obviously, the epidemiology and risk factors of fungal diabetic foot osteomyelitis (DFO) remain poorly understood. Indeed, large series are extremely rare, with the majority of the data being limited to case reports of 1 or 2 patients.
In this context, the findings by Torrence and Schmidt 13 in this issue of the journal are very interesting and useful. In their series of 35 patients undergoing podiatric surgery for clinical and/or radiological evidence of osteomyelitis and nonhealing DFU, 5 (15%) had evidence of fungal osteomyelitis on intraoperative bone specimen culture. Candida albicans, Candida parapsilosis, and Candida glabrata were the specific isolates, but 80% of patients also had concurrent positive bacterial growths. 13 Of note, there were no differences in patient characteristics, white blood cell count, C-reactive protein, and antecedent antibiotic therapy duration or postoperative antibiotic duration between the groups with and without fungal DFO. 13 Some of the observations reported by X et al 13 are novel. First, a prospective follow-up of consecutive patients looking into fungal DFO has not been previously attempted. The authors eloquently highlight the underappreciated possibility of concurrent fungal infection in DFO. The metabolic deregulation following DFO may lead to hyperglycemia and a 11 In addition, many patients with chronic DFU receive multiple courses of broad-spectrum antibiotics, altering the within wound milieu, suppressing normal flora, and thereby allowing the proliferation of opportunistic pathogens. Second, they provide insight into challenges inherent in diagnosis. Indeed, there were no significant differences in patient characteristics that might serve as reliable warning signs for the clinician about the probability of fungal infection. However, the limitations of their study include the small sample size and the selection of patients undergoing surgery.
In light of these new findings, the importance of fungal infection in DFUs merits further appreciation. Larger series are required before drawing definitive conclusions and, perhaps, changing current practice. This endeavor will require multicenter collaboration, which, in turn, will need equilibration of DFU management pathways (including antimicrobial use) and microbiological testing/reporting techniques between recruiting centres.
14 The challenge is obvious, and until then, the small proportion of those with fungal coinfection, tissue or bony, will regrettably be subjected to a delay in diagnosis and, potentially, in wound healing.
In conclusion, concurrent fungal infection may occur in DFO. This knowledge enriches our perceptions on foot infections. 15, 16 Once we acquire additional relevant data, we will be able to consider improving our overall therapeutic algorithms, allowing for such infections.
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